With the promulgation and implementation of the “Regulations on the Management of Clinical Research and Clinical Translational Applications of Biomedical New Technologies” by the country, “cell therapy” and “cell drugs” have entered people’s lives, and also outlined the future blueprint of the life and health industry. On the morning of December 21st, the Clinical Research Center for Regenerative Medicine at Hunan University was awarded and launched at the Yuelu Science and Technology Innovation Port in Changsha. Peng Tao, Deputy Mayor of Changsha Municipal People’s Government, Li Kenli, Vice President of Hunan University, Wang Xianmin, Deputy Director of Xiangjiang New Area Management Committee, and Wang Dezhi, Deputy Secretary General of Changsha Municipal People’s Government, attended the ceremony together. National high-level talent and professor at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Leng Ling, director of the Hunan Provincial Key Laboratory of Organ Injury Aging and Regenerative Medicine, Lv Hongbin, national young talent and professor at the Hunan University Institute of Life Medicine, Lv Kaosheng, and professor at Tongji University and director of Hunan Tat Ka Wai Hong Regenerative Medicine Research Institute (Changsha Jiachen Hospital), Cui Lei, delivered keynote speeches respectively.
The center is led by Hunan University and jointly established with Hunan Cancer Hospital, Xiangya Hospital Organ Injury Aging and Regenerative Medicine Hunan Key Laboratory, Xiangtan Central Hospital, Changsha Third Hospital, Changsha Stomatological Hospital, Changsha Maternal and Child Health Hospital, and Hunan Tat Ka Wai Hong Regenerative Medicine Research Institute. Its aim is to integrate the advantages of “industry university research and medical” collaborative innovation, focus on the diagnosis and treatment of major diseases, tissue and organ damage repair, and other fields, use clinical practice to drive scientific research, empower the industry with professionalism, open up a new path of integrated development of scientific research and industry, and lead the high-quality development of the regenerative medicine industry.
Cell therapy and other regenerative medicine technologies utilize the characteristics of stem cells and immune cells to activate and repair tissues and organs, and are known as the “third medical revolution”. Currently, the global market size for cell therapy has exceeded 400 billion US dollars. Hunan Province is focusing on building a billion dollar stem cell and regenerative medicine industry chain. Changsha City and Xiangjiang New Area are innovating and collaborating to guide Hunan University in jointly building the “Regenerative Medicine Clinical Research Center”. The goal is to take clinical needs as the guide, technological innovation as the engine, and accelerate the formation of a closed loop of “basic research technology development clinical application industrial transformation” through policy innovation, platform support, and industry chain collaboration.
Vice President of Hunan University, Li Kenli, stated that “the center will focus on breakthroughs in key core technologies and solutions for clinical applications, establish a complete stem cell traceability system for cell seed banks and regenerative medicine product banks, create an international level stem cell and regenerative medicine product application testing center, build a regenerative medicine clinical application transformation platform, and strive to produce more high-quality innovative achievements in talent cultivation, technology development, clinical trials, promotion and application in the field of regenerative medicine, to promote the high-quality development of the biopharmaceutical industry
Tat Ka Wai Hong Regenerative Medicine Research Institute is an important strategic layout of Tat Ka Wai Hong in the field of life and health. As a co construction unit of the center, we will fully invest in technology, talents, and funds to accelerate the advancement of cutting-edge therapies from laboratory to clinical practice. Wang Yiqing, Chairman of Tat Ka Wai Hong, said that we have built a cell bank and laboratory that meets GMP standards and an international standard sample storage library for the center’s work. We aim to create a complete industrial chain from cell collection, storage, preparation to application, continuously improve the safety and effectiveness of our products, and enable the people to dare to use, want to use, and use cell therapy products.